Slide 1: Cover letter to stock exchanges
April 30, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Mada
Slide 2: FY 2026 Financial Results
FY 2026 Financial 20 Years Results logo 30/04/2026 © 2026 Laurus Labs Ltd.
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. W
Slide 4: Corporate Overview
1 Corporate Overview FY 2026 3
Slide 5: Laurus @20 years of Transformation & Value creation
Laurus @20 years of Transformation & Value creation Unique story of High quality growth Biggest Wealth creator in Indian Healthcare space ^ 8,000 [₹ Crore] 32x Laurus Labs: 11.6x 6,000 Total Market cap >30% Amongst few companies in BSE 500 index: 3.3x CAGR since 2016 till now 4,000 India which has e
Slide 6: FY 2026 – Accelerated performance backed by Leading commercial offering
FY 2026 – Accelerated performance backed by Leading commercial offering Full Year 2026 in numbers 4Q 2026 ₹6,813 Cr 60.4% 8,200 KL 8,126 ₹1,812 Cr Revenues Gross margin Reactor Employees Revenues +23% +5% volume +15% +5% ₹1,826 Cr ₹1,070 Cr 1.3X 3,134 ₹523 Cr EBITDA margin CAPEX Net debt / EBITDA R&
Slide 7: Strong Execution and Strengthening Future growth
Strong Execution and Strengthening Future growth ARV Commercial Technological Strong Upholding leadership momentum advancement Financials ESG • Continued capacity • Late-stage/Commercial • Build end to end • Strong growth in • Included in S&P leadership supplies of multiple capability to synthesize
Slide 8: Business Division: Strong diversified growth, underpin by integrated model
Business Division: Strong diversified growth, underpin by integrated model Strong diversified performance ARV de-risking continues Transformation continues with consistent rise in CDMO CAGR % FY 26 FY26 Divisions FY 20-26 revenue share and continued decline in ARV share Growth Revenue mix 100% 90% 1
Slide 9: Strengthening Large-scale manufacturing network & capabilities to support customers
Strengthening Large-scale manufacturing network & capabilities to support customers Small Molecules API & FDF R&D Fermentation CGT & ADC Unit 1 & 3, Vizag 3600 kL Unit 6, Vizag 1476 kL R&D & Kilo lab, Hyderabad LB-1 & LB-2, Bangalore CAR-T unit-1, Mumbai 1 +240 kL +600 treatment Unit 5, Vizag 161 kL
Slide 10: Growth CAPEX progress across portfolio
Growth CAPEX progress across portfolio >85% Growth CAPEX in diversified portfolio 21% 20% 27% CAPEX ₹4300 By Phase- Portfolio 11 On-going growth projects Cr1 FY22-26, mix wise (7 API + 2 FDF + 1 Fermentation + 1 Gene 15% of Sales 79% Therapy/ADC) 53% API/CDMO Drug Product Ramp-up Operational On-goin
Slide 11: Exemplary Quality track record - One Quality for all Markets
Exemplary Quality track record - Commitment to “One Quality for all Markets” Last US FDA inspection 132 Quality audit completed in FY26: Regulatory # 4 & Customer # 128 Key Facilities Key Regulatory Certifications Date # audits (since inception) EIR Status Successful Inspections by major Regulators
Slide 12: Advancing ESG agenda, consistently recognized by Global agencies
Advancing ESG agenda, consistently recognized by Global agencies S&P Global ESG Score 81/100 Significant updates • Advanced foam tender installed across manufacturing sites Named in S&P Global Sustainability Yearbook Consecutive “BBB” Improved Score by Member of PSCI as • Focus on decarbonizing cons
Slide 13: Financial Overview
2 Financial Overview FY 2026 12
Slide 14: FY 2026: Strong performance
FY 2026: Strong performance FY26 Financial Summary Comments [₹ Crore] FY26 FY25 Y-o-Y • Revenues : ₹ 6,813 Cr, increased 23% driven by continued strong growth across both CDMO and Affordable Medicine (Generics) division Revenues 6,813 5,554 23% • Gross Margins : 60.4%, increased by 500 bps on better
Slide 15: FY 2026: Robust CDMO execution, supported by growth in Affordable Medicines
FY 2026: Robust CDMO execution, supported by growth in Affordable Medicines FY26 Divisional Revenue Performance FY26 Divisional Mix [₹ Crore] FY26 FY25 Y-o-Y CDMO 2,080 1,534 36% 29% 28% Small molecules 1,896 1,374 38% CDMO 31% Affordable Bio 184 160 15% / +3% over last year Medicines ₹ 6,813 Cr Aff
Slide 16: FY 2026: Financial Position
FY 2026: Financial Position FY26 Balance sheet Increase in net fixed assets [₹ Crore] FY26 FY25 Y-o-Y Increase mainly in property, plant and equipment due to Net Fixed assets (incl. CWIP) 4,879 4,316 +563 • Investments in ADC/Gene Therapy PD lab & cGMP manufacturing facility in Hyderabad site Goodwi
Slide 17: 4Q FY26: Achieved highest Revenue and Operating profits
4Q FY26: Achieved highest Revenue and Operating profits 4Q FY26 Financial Summary Comments [₹ Crore] 3Q FY26 4Q FY26 4Q FY25 Y-o-Y Q-o-Q • Revenues : ₹ 1,812 Cr, increased 5% primarily driven by robust CDMO growth supported by steady Affordable medicine business (led by APIs) Revenues 1,778 1,812 1,
Slide 18: 4Q FY26: Driven by healthy CDMO performance
4Q FY26: Driven by healthy CDMO performance 4Q FY26 Divisional Revenue Performance 4Q FY26 Divisional Mix [₹ Crore] 3Q FY26 4Q FY26 4Q FY25 Y-o-Y Q-o-Q CDMO 451 589 490 20% 31% 25% 29% Small molecules 408 524 461 14% 28% Affordable Bio 43 65 29 124% 51% CDMO 33% Medicines / +4% over last year Afford
Slide 19: Quarterly Performance Summary: Sustained growth momentum
Quarterly Performance Summary: Sustained growth momentum EBITDA & Gross Profit Margins Revenues [₹ Cr] 900 [₹ Cr] 59.4% 59.9% 60.9% 61.4% GPM 56.9% 800 55.1% 55.2% 58.0% 54.5% 1,812 700 1,778 OPM 48.0% 1,720 1,653 28.9% 27.7% 27.3% 600 1,570 38.0% 1,415 26.0% 500 24.8% 1,195 1,224 400 20.1% 28.0% 14
Slide 20: Financial Highlights FY 2020-26
Financial Highlights FY 2020-26 Revenues EBITDA & Gross Profit Margins [₹ Cr] CAGR: 16% [₹ Cr] 4000 CAGR: 21% 70.0% 3500 60.4% 60.0% GPM 3000 55.2% 55.5% 54.1% 55.4% 50.1% 51.7% 50.0% 2500 32.7% 26.8% OPM 29.1% 40.0% 26.4% 2000 6,813 6,041 5,554 20.1% 20.1% 1,826 30.0% 5,041 1500 4,814 4,936 15.8% 2
Slide 21: Business Review & Strategy
3 Business Review & Strategy FY 2026 20
Slide 22: CDMO – Small molecules: Strong demand and operational execution
CDMO – Small molecules: Strong demand and operational execution Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 14% • Strong growth benefitted from late stage pipeline and Q-o-Q ▲ 28% commercial NCE API supplies +38% 1896 • Sustained clinical and commercial contracting across technologies and sites driving g
Slide 23: CDMO – Small molecules: Expanding pipeline and diversified portfolio
CDMO – Small molecules: Expanding pipeline and diversified portfolio Expanding Pipeline & Solid foundation to drive future manufacturing growth • Small molecules pipeline continue to expand, based # Active Projects 125 on trust, capabilities, scale and delivery 110 23 90 20 • Diversified portfolio b
Slide 24: Bio – Healthy demand visibility, robust pipeline building continues
Bio – Healthy demand visibility, robust pipeline building continues Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 124% • Healthy growth through revenue diversification. Continued Q-o-Q ▲ 51% pipeline progress on larger Global accounts +15% 184 • Acceleration in Product development and launch activities 160
Slide 25: Affordable Medicines – Strong execution, Demand led capacity creation continues
Affordable Medicines – Strong execution, Demand led capacity creation continues Revenue Growth Comments [₹ Cr] Y-o-Y ▼ 1% +18% • Strong full year, led by both FDF and API. Sustained volume led Q-o-Q ▼ 8% 4733 ARV leadership and maximized US/EU opportunity on select molecules 4020 2746 • Maintained c
Slide 26: ARV – Leadership and Committed to saving lives globally
ARV – Leadership and Committed to saving lives globally ARV business de-risking continues Industry environment • Overall stable market environment, supported by adequate [₹ Cr] funding by multi-lateral agencies Revenues Share % Chart Title • Dolutegravir use to remain steady over the next couple of
Slide 27: Advanced Biologics – Investments in Gene / ADC platform building continues
Advanced Biologics – Investments in Gene / ADC platform building continues Gene Therapy /ADC cGMP facility in Hyderabad R&D lab already started operations in Dec 2025 Site under construction • Process development lab started in Dec 2025 (technologies at site: Bioconjugation, Plasmids & AAV gene ther
Slide 28: Cell therapy – Accelerate NexCAR adoption and operating leverage
Cell therapy – Accelerate NexCAR adoption and operating leverage New CAR-T GMP facility, Nerul Forward focus Accelerate NexCar19 clinical adoption 22% Expansion of product portfolio 75 Sales 62 Global partnerships & Licensing pathways [₹ Cr] Other material updates FY25 FY26 • BCMA Ph-1 trails ongoin
Slide 29: Earnings call details
Earnings call details Laurus Labs Results Conference Call to be held on Thursday, 30 April 2026 at 5:00 PM IST Dial – In – Details Universal Dial-In +91 22 6280 1384 Click below to Express Join with India Local access Number +91 22 7115 8285 Diamond Pass Singapore +800 1012045 Click here to register
Slide 30: Additional Information
Additional Information Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral